Telix Pharmaceuticals (STU:T3X) 3-Year Revenue Growth Rate : 411.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telix Pharmaceuticals 3-Year Revenue Growth Rate?

Telix Pharmaceuticals's Revenue per Share for the six months ended in Dec. 2024 was €0.73.

During the past 12 months, Telix Pharmaceuticals's average Revenue per Share Growth Rate was 46.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 411.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 230.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Telix Pharmaceuticals was 411.00% per year. The lowest was 157.10% per year. And the median was 283.40% per year.

Competitive Comparison of Telix Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Telix Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Telix Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Telix Pharmaceuticals (STU:T3X) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Telix Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (STU:T3X) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

TLX:USA TLPPF:USA TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals Headlines

No Headlines